Loading insider details...
Beta
Latest Form 4 (Jul 1, 2026): Exercise/Conversion of 5,407 GLUE shares, $72.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 1, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Exercise/Conversion | 5,407 | $72.5K |
| Jun 30, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Exercise/Conversion | 6,000 | $45.4K |
| Jun 25, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Exercise/Conversion | 6,000 | $45.4K |
| Feb 24, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Sale | 9,189 | $179.2K |
| Jan 5, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 31,000 | n/a |
| Jan 6, 2025 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 36,000 | n/a |
| Sep 13, 2024 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 30,000 | n/a |
| Jan 4, 2024 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 121,000 | n/a |
| Jan 4, 2023 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 135,000 | n/a |
| Dec 19, 2022 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 36,000 | n/a |